Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Acumen Pharmaceuticals, Inc. ABOS

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 16, 2026 8-K 14 signals fired
Core
Clinical Trial Result Combination Therapy Mentioned Indication Expansion Clinical Hold
Other
Interim Data Positive Publication Positive Patient Retention High Fast Track Designation Received Ce Mark Received Fda Aligned Safety Differentiated Fda Breakthrough Device Designation Fast Track Granted
Biotech Risk
Accelerated Approval
Aug 12, 2026 8-K 10 signals fired
Other
Net Loss Reported Safety Differentiated Patient Retention High Kol Endorsement Interim Data Positive
Core
Clinical Trial Result Secondary Endpoint Mentioned Lead Asset Progress Indication Expansion
Biotech v3
Ind Submission Planned
Aug 12, 2026 10-Q 43 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Segment Aggregation Disclosure Employment Termination Upon Death Personnel Cost Decrease Disclosure Emerging Growth Company Status Disclosed Codm Segment Reporting Disclosure Equity Plan Share Reserve Disclosure Financing Activities Cash Flow Disclosure Net Loss Reported Other Income Expense Disclosure Equity Award Plan Types Enumerated Equity Award Non Transferability Clause Equity Plan Amendment Restriction Share Withholding Tax Settlement
Core
Secondary Endpoint Mentioned
Jun 16, 2026 8-K 10 signals fired
Biotech v3
Ind Submission Planned
Core
Clinical Trial Result Indication Expansion Lead Asset Progress Clinical Hold
Other
Fast Track Granted Interim Data Positive Orphan Status Granted Patient Retention High
Biotech Risk
Accelerated Approval
Jun 3, 2026 8-K 2 signals fired
Other
Classified Board Director Election Quorum Presence Disclosed
May 12, 2026 10-Q 33 signals fired · top 15
Other
Cash Flow Statement Investing Activities Ipo Or Capital Raising Completion Codm Segment Reporting Disclosure Institutional Investment Form S3 Shelf Registration Disclosure Segment Aggregation Disclosure Personnel Cost Decrease Disclosure Financing Activities Cash Flow Disclosure Other Income Expense Disclosure Liquidity Position Snapshot Disclosed Net Loss Reported Interim Data Positive Stock Option Intrinsic Value Disclosure Enrollment Ahead Of Schedule
Core
Lead Asset Progress
May 12, 2026 8-K 11 signals fired
Other
Net Loss Reported Liquidity Position Snapshot Disclosed Administrative Efficiency Personnel Cost Decrease Disclosure Burn Rate Controlled Ipo Or Capital Raising Completion Kol Endorsement
Core
Secondary Endpoint Mentioned Indication Expansion Lead Asset Progress Clinical Hold
Mar 26, 2026 8-K 22 signals fired · top 15
Other
Net Loss Reported Personnel Cost Decrease Disclosure Administrative Efficiency Burn Rate Controlled Interim Data Positive Liquidity Position Snapshot Disclosed Patient Retention High Expanded Access Program Active Safety Differentiated Enrollment Ahead Of Schedule Publication Positive
Core
Clinical Trial Result Lead Asset Progress Indication Expansion
Biotech v3
Ind Submission Planned